...
机译:贝伐单抗结合的半月刊卡培他滨和伊立替康,一线治疗转移性大肠癌患者癌症。
Medical Oncology service, Hospital General Universitario Gregorio Maranon, C/ Doctor Equerdo, 46, Madrid 28007, Spain.;
irinotecan; Bevacizumab; CapecitabineRegimenpatient treatmentPatientsmetastatic colorectal cancer;
机译:Surgical resectability of multisite metastatic colorectal cancer: Pushing the limits while appropriately selecting patients
机译:改进的Xeliri(Capecitabine Plus Irinotecan)与Folfiri(Leucovorin,Fluyouracil和Irinotecan),无论是在还是没有bevacizumab,作为转移性结肠直肠癌的二线治疗(Axept):多期,开放标签,随机,非劣势 ,第3阶段试验
机译:Capiri(Capecitabine,Irinotecan)加上Bevacizumab vs folfiri(Folinic Acid(Folinic Acid,5-Fluorouracil,irinotecan)加上贝伐单抗作为一线治疗无法切除/转移/转移性大肠癌(MCRC)的患者的一线治疗,
机译:CD31评估的微血管密度预测北伐单抗治疗在转移性结肠直肠癌中的临床益处:热情研究的结果翻译前期研究Capecitabine和Irinotecan Plus Bevacizumab然后是Capecitabine和Oxaliplatin加贝伐单抗或MCRC患者的逆向序列
机译:CD31评估的微血管密度预测北伐单抗治疗在转移性结肠直肠癌中的临床益处:热情研究的结果,翻译前期研究Capecitabine和Irinotecan Plus Bevacizumab,然后是Capecitabine和Oxaliplatin加贝伐单抗或MCRC患者的逆向序列